Therapies after first-line afatinib in patients with EGFR m+ NSCLC in Japan: Retrospective analysis of LUX-Lung 3

Hiroshige Yoshioka, Terufumi Kato, Isamu Okamoto, Hiroshi Tanaka, Toyoaki Hida, Takashi Seto, Katsuyuki Kiura, Yahui Tian, Hisaya Azuma, Nobuyuki Yamamoto

Research output: Contribution to journalArticle


Aim: Acquired resistance to EGFR tyrosine kinase inhibitors is inevitable in non-small-cell lung cancer. To inform subsequent treatment decisions, we retrospectively assessed therapies following afatinib in Japanese patients from LUX-Lung 3. Patients & methods: LUX-Lung 3 was a randomized, open-label, Phase III study of afatinib versus cisplatin/pemetrexed in treatment-naive patients with EGFR mutation-positive (EGFRm+) advanced lung adenocarcinoma. Results: Among 47 Japanese patients who discontinued first-line afatinib, 91/81/62% received ≥one/two/three subsequent therapies. The most common second-line therapies were platinum-based chemotherapy (38%) and a first-generation EGFR tyrosine kinase inhibitor (17%). Median overall survival (afatinib vs cisplatin/pemetrexed) was 47.8 versus 35.0 months (not significant). Conclusion: First-line afatinib does not appear to diminish suitability for subsequent therapies in EGFRm+ non-small-cell lung cancer.

Original languageEnglish
Pages (from-to)49-60
Number of pages12
JournalFuture Oncology
Issue number4
Publication statusPublished - Jan 1 2020


All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this